We aim to develop and market cardiovascular products that lower peri-operative risks and provide optimal quality of life for patients

The 21st century valve: “A bio-prosthetic valve, with very low trans-valvular pressure gradient, easy to implant."
Professor Alain Carpentier (Paris 2003)

Leman Cardiovascular is an international biomedical device company, founded in late 2004, present in Europe and in the United States. The company was set up to create the third generation biological heart valve and thereby respond to an unmet surgical need. An estimated 17 million people die of cardiovascular heart diseases every year. Heart valve disease affects some half a million people worldwide.

Leman Cardiovascular is financially independent and aims to be a significant player in the cardiovascular device market. The company’s aim is to manufacture and sell a novel third generation bio-prosthetic heart valve and subsequently other products in the field of cardiovascular surgery.

Our mission is to make thereby cardiac surgeons’ life easier, to develop and market cardiovascular products that lower peri-operative risks and therefore to provide optimal quality of life for patients.

With top notch scientific and technological know-how, a strong IP position and solid technical expertise to comply with FDA and EU requirements, the company is well positioned to become a significant player in the market. Furthermore, Leman Cardiovascular is developing a savvy marketing strategy aligned with current best practices.